Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX)

81.37
Delayed Data
As of 4:14pm ET
 +0.46 / +0.57%
Today’s Change
71.46
Today|||52-Week Range
103.73
+10.45%
Year-to-Date
4 Drug Stocks Poised to Surprise this Earnings Season
3:19pm / Zacks.com - Paid Partner Content
Why Vertex Pharmaceuticals Stock Sank 42% in 2016
Jan 17 / MotleyFool.com - Paid Partner Content
3 Beaten-Down Biotech Stocks You Can Buy Right Now
Jan 19 / MotleyFool.com - Paid Partner Content
Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
Jan 12 / Zacks.com - Paid Partner Content
Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?
Jan 19 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short
Jan 11 / Zacks.com - Paid Partner Content
Concert Offers Update on Cystic Fibrosis Drug, Stock Down
Jan 18 / Zacks.com - Paid Partner Content
5 Ways Vertex Pharmaceuticals Plans to Grow in 2017 and Beyond
Jan 09 / MotleyFool.com - Paid Partner Content
Why Vertex Pharmaceuticals (VRTX) Could Be Positioned for a Surge
Jan 18 / Zacks.com - Paid Partner Content
Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
Jan 09 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close80.91
Today’s open81.47
Day’s range80.89 - 82.46
Volume1,105,561
Average volume (3 months)1,971,574
Market cap$20.1B
Dividend yield--
Data as of 4:14pm ET, 01/20/2017

Growth & Valuation

Earnings growth (last year)+26.43%
Earnings growth (this year)+170.48%
Earnings growth (next 5 years)+67.00%
Revenue growth (last year)+77.86%
P/E ratioNM
Price/Sales29.41
Price/Book21.20

Competitors

 Today’s
change
Today’s
% change
MYLMylan NV+0.12+0.32%
INCYIncyte Corp-0.31-0.26%
BMRNBiomarin Pharmaceuti...-1.53-1.78%
BAXBaxter International...-0.34-0.73%
Data as of 4:01pm ET, 01/20/2017

Financials

Next reporting dateJanuary 26, 2017
EPS forecast (this quarter)$0.28
Annual revenue (last year)$1.0B
Annual profit (last year)-$556.3M
Net profit margin-53.89%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Jeffrey M. Leiden
EVP, Chief Operating &
Financial Officer
Ian F. Smith
Corporate headquarters
Boston, Massachusetts

Forecasts


Search for Jobs